跳至主要内容
临床试验/EUCTR2009-010147-14-IT
EUCTR2009-010147-14-IT进行中(未招募)不适用

A diagnostic interventional, controlled, cross-sectional evaluation of joint status using MRI in subjects with severe hemophilia A treated with primary prophylaxis, secondary prophylaxis, or on-demand therapy - ND

Bayer Healthcare AG0 个研究点目标入组 250 人开始时间: 2009年12月28日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Test subjects (for MRI quality assessment):
  • Males aged 18 - 35 years Severe hemophilia A (< 1% FVIII:C) Written informed consent by subject
  • Investigation subjects only (subjects participating in the full investigation):
  • Males aged 12 - 35 years Severe hemophilia A ( < 1 % FVIII:C) No history of Factor VIII inhibitory antibody measured using the Bethesda assay (< 0.6 BU/ml) For prophylaxis groups, having received at least two prophylactic infusions per week for 45 weeks per year for the prevention of bleeding without relevant interruption for a consecutive period beginning at prophylaxis initiation and continuing until the present. Relevant interruption is defined as having received therapy that does not qualify as prophylaxis by the above definition or missing documentation of bleeds and consumption for more than 12 consecutive months. Complete documentation of joints bleeds and their locations prior to start of primary prophylaxis, documentation of the joint status or the joint bleeds and their location of the previous 6 months before start in case of secondary prophylaxis. Bleeding history and/or treatments received during the last 5 years documented in the subjects medical records. The minimum data required is the number and location of joint bleeds, treatment schedule, and Factor VIII consumption over the last 5 years. For the on-demand subjects > 12 bleeds/year in the last 5 years. Written informed consent by subject and parent/legal representative, if < 18 years
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Test Subject:
  • Individuals for whom high-magnetic exposure is contraindicated
  • Individuals who, in the opinion of the physician, would not be able to meet the requirements of the MRI technique
  • Investigation subjects only (subjects participating in the full investigation):
  • Individuals with other coagulopathies (e.g., von Willebrand disease) HIV seropositive subjects Individuals for whom the most clinically severe joint is not one of the 4 index joints (ankle, knee) HCV seropositive individuals who underwent interferon therapy during the last 12 months Individuals for whom high-magnetic exposure is contraindicated (see section 7.1) Individuals who, in the opinion of the physician or parent/guardian, would not be able to meet the requirements of the MRI technique Synovectomy performed within the six months prior to investigation enrollment or orthopedic surgery planned to be performed within the investigation period Joint replacement For the on-demand treatment group, any period greater than 8 consecutive months having received ≥ 50 IU per kg per week Factor VIII for the prevention of bleeding.

研究者

相似试验

A diagnostic interventional, controlled,... | 临床试验